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Objective: To examine whether a history of periodontitis (PD) before anti-diabetic treatment 
is associated with risk of rheumatoid arthritis (RA) development in newly-treated diabetes 
mellitus (DM) patients.
Methods: We conducted a population-based retrospective cohort study using the 1997-2009 
National Health Insurance (NHI) claims data of one million representative individuals from 
all NHI enrollees. Adults with DM (aged ≥20 years) starting anti-diabetic treatment during 
2001–2009 were classified as newly-treated DM patients. We identified 7097 DM subjects 
with PD history within one year before initiating anti-diabetes treatment (index date). By 
matching these 7097 subjects for age on the index date, sex, and year of the index date, we 
randomly extracted 14,194 DM subjects without PD history within one year before anti-
diabetic treatment. Adjusted hazard ratios (aHRs) with a 95% confidence interval (CI) were 
calculated by applying Cox proportional hazards models to quantify the association be-
tween PD history and RA risk.
Results: Compared with DM patients without PD exposure within one year before anti-diabetic 
treatment, crude HR and adjusted HR of RA among DM patients with PD exposure within one 
year before anti-diabetic treatment were 4.51 (95% CI, 1.39–14.64) and 3.77 (95% CI, 1.48–9.60).
Conclusion: PD exposure within one year before anti-diabetic treatment was associated with 
increased RA risk in newly treated DM patients. The lack of knowledge about individual 
smoking status is a major limitation of this study.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Exposição à periodontite no intervalo de um ano antes do tratamento 
antidiabético e risco de artrite reumatoide em pacientes com diabete 
mellitus: estudo de coorte populacional
Palavras-chave:
Diabetes melittus
Periodontite
Artrite reumatoide
Risco
Banco de dados administrativos
r e s u m o
Objetivo: Examinar se uma história de periodontite (PD) antes do tratamento antidiabético 
está associada a risco de ocorrência de artrite reumatoide (AR) em pacientes com diabetes 
melittus (DM) tratados de novo.
Métodos: Fizemos um estudo retrospectivo populacional com os dados de reivindicações do 
National Health Insurance (NHI) de 1997-2009 referentes a um milhão de indivíduos represen-
tativos da totalidade de matriculados. Adultos com DM (≥ 20 anos) que iniciaram o trata-
mento antidiabético durante 2001-2009 foram classificados como pacientes DM tratados de 
novo. Identificamos 7.097 indivíduos DM com história de PD em um intervalo de um ano an-
tes do tratamento antidiabético (data-índice). Na equiparação desses 7.097 indivíduos para 
idade por ocasião da data-índice, gênero e ano da data-índice, extraímos aleatoriamente 
14.194 pacientes DM sem história de PD em um intervalo de um ano antes do tratamento 
antidiabético. As razões de risco ajustadas (aRR) com um intervalo de confiança (IC) de 95% 
foram calculadas mediante a aplicação do modelo de riscos proporcionais de Cox com o 
objetivo de quantificar a associação entre história de PD e risco de AR.
Resultados: Em comparação com pacientes DM sem exposição à PD no intervalo de um ano 
antes do tratamento antidiabético, RR bruta e RR ajustada para AR entre pacientes DM e 
com exposição à PD no intervalo de um ano antes do tratamento antidiabético foram, res-
pectivamente, 4,51 (IC 95%, 1,39-14,64) e 3,77 (IC 95%, 1,48-9,60). 
Conclusão: A exposição à PD no intervalo de um ano antes do tratamento antidiabético foi 
associada a maior risco de AR em pacientes DM tratados de novo. A ausência do status de 
tabagismo em nível individual é importante limitação desse estudo.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
ease characterized by chronic synovial inflammation with 
periarticular osteoporosis and bone erosion, associated with 
an increased risk of cardiovascular disease comparable to 
that of diabetes mellitus (DM).1 Although the exact etiology 
is still unknown, the interaction between environmental fac-
tors and genetic factors has been found to play a role in RA 
pathogenesis.2 Smoking is a well-known risk factor,3-10 and 
recently periodontitis (PD) has emerged as another environ-
mental risk factor for RA.11,12 PD is a common chronic, mi-
crobially triggered an inflammatory disorder that causes an 
irreversible loss of the supporting tooth structures, and may 
ultimately lead to tooth loss.13 It affects approximately half of 
the population aged ≥ 30 years in the United States.14,15 One 
of the major PD-related pathogens, Porphyromonas gingivalis (P. 
gingivalis), is the only microorganism that produces peptidy-
larginine deiminase, which may cause citrullination.16 In ge-
netically susceptible individuals, the breakdown of immune 
tolerance to citrullinated peptides may lead to the production 
of anti-cyclic citrullinated peptide (anti-CCP) antibodies, as-
sociated with RA development.17 The presence of P. gingivalis 
DNA in the serum and synovial fluid and a strong correlation 
between the presence of anti-CCP antibodies and the pres-
ence of PD in RA patients support this hypothesis.18-20
In recent years, increasing evidence has indicated a bidi-
rectional association between DM and PD.21,22 PD is associated 
with increased incident DM risk, poor glycemic control, and 
DM complications,23-26 probably due to the higher levels of 
systemic proinflammatory mediators that exacerbate insu-
lin resistance.22 A number of observational studies also show 
a greater prevalence, severity, extent, or progression of one 
or more PD indicators in DM patients, with type 1, type 2, or 
gestational diabetes, as compared to those in non-DM sub-
jects.27-35
Hyperglycemia has been found to modify PD expression,36 
by interfering with the host response and causing an exces-
sive inflammatory response to infection,37,38 as well as by the 
interaction of the receptor for advanced glycation end prod-
ucts (RAGE) with its ligands in gingiva.22,36,39 Several previous 
studies have shown that DM patients have defective neutro-
phil function,40-42 which may lead to impaired clearance of 
P. gingivalis, the major periodontal bacterium related to RA 
pathogenesis.17 In diabetic mice, inoculation with P. gingiva-
lis leads to prolonged and exaggerated systemic cytokine ex-
pression and inflammatory infiltrates in a model of calvarial 
infection.37,38 Hence, we hypothesize that the prolonged chal-
lenge presented by the oral bacteria as a result of the defective 
host response, together with the exaggerated and sustained 
inflammatory response to the bacteria, may cause more se-
vere PD in DM subjects than in non-DM subjects with PD. Re-
cent studies show a dose-dependent association between PD 
exposure and RA risk.11,12 Because hyperglycemia is present 
for some time before commencing anti-diabetic treatment in 
DM patients,43 we hypothesize that among newly-treated DM 
patients, those who had PD exposure within one year before 
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anti-diabetic treatment may have a higher risk of RA develop-
ment than those without PD exposure within one year before 
anti-diabetic treatment.
To the best of our knowledge, no population-based co-
hort study has examined whether RA risk differs between 
newly-treated adults with and without a history of PD 
before anti-diabetic treatment. Recently, the Taiwanese 
National Health Insurance Research Database (NHIRD) 
had facilitated population-based longitudinal studies. We 
therefore took advantage of this resource to conduct this 
cohort study to estimate the hazard ratios (HRs) for the as-
sociation between PD history and RA development in new-
ly-treated DM patients.
Methods
Data source
The source of data was the NHIRD, which covered claims of 
ambulatory care, inpatient services and dental services, and 
prescriptions during 1997-2009. In March 1995, the National 
Health Insurance (NHI) program was implemented, and it has 
since covered more than 98% of the population. The National 
Health Research Institute, which manages the NHIRD, has 
released comprehensive NHI-related administrative claims 
data for research. In 2000, the NHIRD randomly selected one 
million participants to form a representative database for 
study purposes. Here we used one million representative 
subjects from the multiple datasets of the NHIRD: ambula-
tory and inpatient claims files, enrollment files, and the NHI 
catastrophic illness files, all from 1997-2009. The NHI cata-
strophic illness files were established to track patients with 
major or catastrophic illnesses, including cancer, end-stage 
renal disease, mental illness, congenital illness, and several 
autoimmune diseases, including RA. The Bureau of National 
Health Insurance (BNHI) routinely reviews the original medi-
cal charts of all patients who applied for catastrophic illness 
registration to validate the diagnoses. The American College 
of Rheumatology classification criteria for RA (1987) was 
used to validate RA diagnosis for the period 1997–2009.44 The 
ambulatory and inpatient files include information on date 
of visit/admission, diagnoses, examinations, procedures, 
and medical expenses. The enrollment files provide enroll-
ment and demographic information. Although the dataset 
lacked laboratory and radiographic data, the BNHI periodi-
cally audited the accuracy of diagnoses by randomly sam-
pling patient charts to check claims.45 The Ethics Committee 
of Clinical Research at Taichung Veterans General Hospital 
approved this study.
Study samples
DM subjects
In this retrospective cohort study, we identified patients who 
had at least one diagnosis of DM [International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD9-CM) code 
250×] with concurrent prescription of any anti-diabetes medi-
cation for more than 28 days after January 1, 2001 and classi-
fied these as DM subjects.
Subjects with and without PD history
In Taiwan, BNHI covers the cost of dental scaling a maximum 
of twice per year for each individual, with the aim of improv-
ing dental health. For these patients, dentists may perform 
scaling for these people with a concurrent PD coding (ICD9-
CM codes 523.3–5). Therefore, we defined PD exposure as hav-
ing a diagnosis of PD (ICD9-CM codes 523.3–5) together with 
concurrent antibiotic therapy, or with periodontal treatment 
other than dental scaling by certified dentists. PD history was 
defined as having PD during the one year before the index 
date. Patients who had not been diagnosed with periodontal 
disease (ICD9-CM Codes 523×) within one year before the in-
dex date were classified as patients with no PD history.
Exclusion criteria
All individuals diagnosed with RA (ICD9-CM code 714.0) be-
fore the index date or aged younger than 20 years on the in-
dex date were excluded.
Matched study subjects
The first date of anti-diabetic treatment was defined as the 
index date. First, we identified a total of 7097 DM subjects 
with PD history. To match these DM subjects with PD history 
in terms of age on the index date (i.e., 20–34, 35–49, 50–64, 
≥ 65 years), sex, and the year of the index date, we randomly 
selected 14,194 DM subjects with no PD history.
Outcome variable
Patients who had ambulatory visits coded for RA (ICD9-CM 
Code 714.0) and certificates of the catastrophic illness for RA 
were classified as RA cases. The outcome variable was the 
time (in years) from the index date to the date of their first 
ambulatory care visit with a concurrent RA diagnosis. If the 
study subjects withdrew from the Taiwanese NHI system for 
any reason, such as death or moving away, the date of with-
drawal was selected as the censored date, otherwise the last 
date of the dataset (December 31, 2009) was used.
Potential confounders
The study included the insurable wage and urbanization level 
of the study subjects as potential confounders. In Taiwan, the 
insurable wage was calculated from the average monthly in-
come of the participants, which served as an economic index. 
If the insurable earnings of the subject was zero, the insur-
able wage was treated as dependence. The insurable wage 
was converted from new Taiwan dollars (TWD) to USD using a 
conversion rate of 30 TWD to 1 USD. The insurable wage was 
transferred to ordinal variables (i.e., dependence, 1–700 USD 
and > 700 USD). We selected 700 USD as the cut-off value for 
insurable wage because it was the median of the insurable 
wages among subjects whose insurable earnings were not 
zero. Based on the previously stratified seven clusters [from 
level 1 (most urbanized) to level 7 (least urbanized), in Tai-
wan,46 the urbanization level was converted into 3 levels: ur-
ban (levels 1–2), suburban (levels 3–4), and rural (levels 5–7).
Statistical analysis
We compared baseline characteristics based on PD history 
using a t-test for continuous variables, and Pearson’s χ2 or 
127R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 2 ) : 1 2 4 – 1 3 0
Fisher’s exact test for categorical variables. Adjusting for age, 
sex, insurable wage and urbanization level of subjects, Cox 
proportional regression analysis was used to estimate inci-
dent RA risk associated with PD history, as shown by adjusted 
hazard ratios (HRs) with 95% confidence intervals (CIs). A two-
tailed P-value of < 0.05 was considered statistically significant. 
All statistical calculations were performed using SPSS version 
18.0 for Windows (SPSS, Inc., Chicago, IL).
Sensitivity analysis
We conducted lag analyses by advancing the RA diagnosis 
date by 3 months, 6 months, and 1 year and examined the 
potential impact of insidious RA onset. We then repeated 
the Cox proportional regression analyses after exclud-
ing those whose follow-up time was less than 3 months, 
6 months, or 1 year, and subtracting the follow-up time by 
3 months, 6 months and 1 year respectively, as the revised 
follow-up time.
Results
A total of 21,291 DM subjects were followed for a median 
(interquartile range) of 3.4 (1.5, 5.9) years; of these, 19 sub-
jects developed incident RA. The demographic and clinical 
data according to PD history are shown in Table 1. The mean 
patient age ± SD was 57.5 ± 12.8 years and women comprised 
43.3% of all study subjects.
Among the 7,097 DM subjects with a history of PD ex-
posure within one year before the index date, 12 subjects 
developed RA after 26,910 person/years of follow-up and 
the incidence was 44.6 cases per 105 person/years. Among 
the 14,194 DM subjects without PD history, 7 subjects de-
veloped RA after. From 54,002 person/years of follow-up, 
the incidence was 13 cases per 100,000 person/years. Com-
pared with subjects without PD history, the crude HR of in-
cident RA among those with PD history was 4.51 (95% CI 
1.39–14.64). As shown in Table 2, after adjusting for age, sex, 
insurable wage, and urbanization level of the subjects, the 
adjusted HR (aHR) of RA associated PD history remained 
statistically significant (aHR, 3.77; 95% CI 1.48–9.60). The 
survival curve for incident RA among DM individuals is 
shown in Figure 1. 
Table 3 shows the results of sensitivity analyses conduct-
ed by varying the lag time of RA diagnosis considering the 
insidious RA onset. The association between PD history and 
RA risk remained statistically significant after varying the 
lag time.
Discussion
This study is the first population-based cohort study to use 
administrative data to examine the strength of the associa-
tion between PD history within one year before anti-diabetic 
treatment and RA risk in newly-treated DM patients. This 
study focuses on PD exposure history within one year before 
anti-diabetic treatment because we hypothesize that hy-
perglycemia may exist during this period, and thus interact 
Table 1 – Comparison of demographic data for patients 
based on periodontitis (PD) history within one year 
before the index date in newly-treated diabetic patients.
Variable PD history
(n = 7097)
No PD 
history
(n = 14194)
p
Female 3074 (43.3) 6148 (43.3) 1.000
Age (years) 1.000
20–34 238 (3.4) 476 (3.4)
35–49 1660 (23.4) 3320 (23.4)
50–64 3121 (44.0) 6242 (44.0)
≥ 65 2078 (29.3) 4155 (29.3)
Urbanization level < 0.001
Urban 2748 (38.7) 4873 (34.3)
Suburban 2854 (40.2) 5990 (42.2)
Rural 1495 (21.1) 3331 (23.5)
Insurance amount 
(USD)
< 0.001
Dependence 440 (6.2) 894 (6.3)
1–700 3069 (43.2) 6919 (48.7)
>700 3588 (50.6) 6381 (45.0)
RA, rheumatoid arthritis; DM, diabetes mellitus; PD history, a history 
of periodontitis within one year before anti-diabetic treatment.
Table 2 – Adjusted hazard ratios (HRs) with 95% 
confidence intervals (CIs) of RA risk associated with 
variables in newly-treated DM patients.
Variável HR (95% CI) p value
A history of PD 3.77 (1.48–9.60) 0.006
Female 6.04 (1.73–21.05) 0.005
Age, incremental year 1.04 (1.00–1.08) 0.085
Urbanization level
Urban Reference -
Suburban 1.34 (0.44–4.14) 0.608
Rural 1.67 (0.50–5.54) 0.405
Insurable wage (USD)
Dependence Reference -
1–700 3.35 (0.43–26.00) 0.248
> 700 1.43 (0.13–15.33) 0.767
RA, rheumatoid arthritis; DM, dabetes mellitus; PD, periodontitis; 
USD, United States dollar.
with PD to drive an increased RA risk. The main finding of 
our study is that the association between PD history and RA 
development is statistically significant among newly treated 
DM individuals. In addition, if the lag time of RA diagnosis is 
considered, this association became stronger.
The results of this cohort study further supports the the-
ory that PD history is associated to RA development, which 
was also suggested by the results of two recent case–con-
trol studies.11,12 However, the results of another large cohort 
study on American women indicated that PD was not asso-
ciated with RA risk.47 Of note, DM status was not taken into 
account in this previous cohort study, and no male subjects 
were included.47
The main strength of this study is that the use of popu-
lation-based samples of Taiwanese women and men could 
avoid selection bias and the results should be applicable to 
the general population of Taiwan. Furthermore, to increase 
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internal validity, this study matched study subjects with re-
garding age, sex, and the year of the index date, and fur-
ther adjusted potential confounders including the insurable 
wage and urbanization level of subjects. However, a num-
ber of limitations must be considered. First, the accuracy 
of diagnoses in administrative data is an area of concern. 
Bias due to misclassifi cation or miscoding of PD and RA can 
still occur despite regular audit of the quality of claims car-
ried out by periodically sampling patient charts, which is 
randomly performed by the BNHI. However, the accuracy of 
RA diagnosis is of less concern, because the issue of a cata-
strophic illness certifi cate for RA diagnosis requires valida-
tion by at least two qualifi ed rheumatologists and involves 
checking the medical charts, radiographic fi ndings, and lab-
oratory data. In addition, the inclusion of periodontal treat-
ment in the diagnostic criteria of PD also helps increase 
the accuracy of diagnoses. Moreover, the non-differential 
misclassifi cation of RA and PD diagnoses would have bi-
ased the results towards the null. Second, use of the NHIRD 
precluded further adjustment of unmeasured potential con-
founders, such as serum glucose level, glycated hemoglobin, 
anti-CCP antibodies, HLA-DRB1, and smoking status of sub-
jects. Third, the small number of incident RA cases limits 
the number of covariates for adjustment. Finally, the results 
of this population-based study in Taiwan might not be used 
to generalize other ethnic populations.
Conclusion
This nonselective, population-based cohort study indicates 
that PD history within one year before anti-diabetic treat-
ment is associated with increased RA risk in newly treated 
DM patients. Further clinical and basic studies need to be 
performed to elucidate whether the degree of hyperglycemia 
interacts with RA risk associated with PD exposure.
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Fig. 1 – Free of incident rheumatoid arthritis rates among 
subjects with diabetes mellitus stratifi ed by periodontitis 
history.
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Table 3 – Sensitivity analyses for RA risk associated 
with PD history by varying the lag time of RA diagnosis, 
as shown by adjusted hazard ratios (HRs) with 95% (CIs).
Lag time PD history No PD 
history
HR (95% CI)
n, RA/total 
(%)
n, RA/total 
(%)
No lag time 12/7097 (0.17) 7/14194 (0.05) 3.77 (1.48–9.60)
3 months 12/6801 (0.18) 5/13654 (0.04) 5.31 (1.86–15.14)
6 months 11/6529 (0.17) 5/13034 (0.04) 4.86 (1.68–14.08)
1 year 9/5918 (0.15) 4/11835 (0.03) 5.12 (1.57–16.74)
RA, rheumatoid arthritis; DM, diabetes mellitus; PD, periodontitis; 
PD history, a history of periodontitis within one year before anti-
diabetic treatment. 
Cox regression analyses were conducted after adjusting for age, 
sex, urbanization level, and insurable wage of subjects.
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